A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.

@article{Glasmacher2006ASR,
  title={A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.},
  author={Axel G Glasmacher and Corinna Hahn and Florian Hoffmann and Ralph Naumann and Hartmut Goldschmidt and Marie von Lilienfeld-Toal and Katjana S Orlopp and Ingo G. H. Schmidt-Wolf and Marcus Gorschlueter},
  journal={British journal of haematology},
  year={2006},
  volume={132 5},
  pages={584-93}
}
The activity of thalidomide in relapsed or refractory multiple myeloma is widely accepted but not yet demonstrated in a randomised-controlled trial. A systematic review of the published clinical trials of these patients could reduce the possible bias of single phase-II studies. A systematic search identified 42 communications reporting on 1674 patients. Thirty-two trials used an escalating dosing regimen and four a fixed dose regimen (one dose with 50 mg/d, three doses with 200 mg/d). The… CONTINUE READING